Drug · DIN 02212153
IMITREX DF
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since October 27, 2025; first marketed February 11, 1998.
- Drug Identification Number (DIN)
- 02212153
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Sumatriptan N02CC01
- Class
- Human
- Record last updated
- January 5, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SUMATRIPTAN (SUMATRIPTAN SUCCINATE) | 50 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 13, 2004: NOC 2873Supplement to a New Drug Submission (SNDS) · Product name change from imitrex
- July 18, 2001: NOC 2563New Drug Submission (NDS) · Change in manufacturer name
- March 7, 1996: NOC 4682New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “imitrex”. A notice may cover another product or only some lots: read it to see what it covers.
- Imitrex (2013-11-01)November 21, 2013 · Drugs · Product safety · Type I